文献リスト

1) Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimerʼs disease: recommendations from the National Institute on Aging-Alzheimerʼs Association work-groups on diagnostic guidelines for Alzheimerʼs disease. Alzheimers Dement. 2011; 7: 280-92

2) Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimerʼs disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55: 306-19

3) Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimerʼs disease. Brain. 2008; 131(Pt 6): 1630-45

4) Leinonen V, Alafuzoff I, Aalto S, et al. Assess-ment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomo-graphy with carbon 11-labeled Pittsburgh Com-pound B. Arch Neurol. 2008; 65: 1304-9

5) Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimerʼs disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010; 9: 363-72

6) Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009; 66: 1557-62

7) Bao F, Wicklund L, Lacor PN, et al. Different beta-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging. 2011 Jun 15

8) Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007; 27: 6174-84

9) Koivunen J, Verkkoniemi A, Aalto S, et al. PET amyloid ligand [11C]PIB uptake shows predomi-nantly striatal increase in variant Alzheimerʼs disease. Brain. 2008; 131(Pt 7): 1845-53

10) Villemagne VL, Ataka S, Mizuno T, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009; 66: 1537-44

11) Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011; 69: 181-92

12) Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009; 65: 557-68

13) Tolboom N, Yaqub M, van der Flier WM, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med. 2009; 50: 191-7

14) Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimerʼs disease: a new lexicon. Lancet Neurol. 2010; 9: 1118-27

15) Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimerʼs disease: recommendations from the National Institute on Aging-Alzheimerʼs Asso-ciation workgroups on diagnostic guidelines for Alzheimerʼs disease. Alzheimers Dement. 2011; 7: 270-9

16) Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009; 73: 754-60

17) Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology. 2011; 76: 1085-90

18) Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006; 67: 446-52

19) Hatashita S, Yamasaki H. Clinically different stages of Alzheimerʼs disease associated by amyloid deposition with [11C]-PIB PET imaging. J Alzheimers Dis. 2010; 21: 995-1003

20) Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010; 67: 122-31

21) Resnick SM, Sojkova J, Zhou Y, et al. Longitu-dinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010; 74: 807-15

22) Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009; 72: 1487-94

23) Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimerʼs disease. Proc Natl Acad Sci U S A. 2009; 106: 6820-5

24) Morishima-Kawashima M, Oshima N, Ogata H, et al. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumu-lation in the human brain. Am J Pathol. 2000; 157: 2093-9

25) Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006; 59: 512-9

26) Fagan AM, Mintun MA, Shah AR, et al. Cerebro-spinal fluid tau and ptau(181) increase with cor-tical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimerʼs disease. EMBO Mol Med. 2009; 1: 371-80

27) Ances BM, Christensen JJ, Teshome M, et al. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology. 2010; 75: 111-5

28) Sojkova J, Zhou Y, An Y, et al. Longitudinal patterns of beta-amyloid deposition in non-demented older adults. Arch Neurol. 2011; 68: 644-9

29) Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimerʼs disease. Neurobiol Aging. 2010 Aug 3

30) Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009; 73: 1186-92

31) Grimmer T, Tholen S, Yousefi BH, et al. Progression of cerebral amyloid load is asso-ciated with the apolipoprotein E epsilon4 geno-type in Alzheimerʼs disease. Biol Psychiatry. 2010; 68: 879-84

32) Chételat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010; 67: 317-24

33) Becker JA, Hedden T, Carmasin J, et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2011; 69: 1032-42

34) Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010; 67: 584-7

35) Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progres-sion from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009; 66: 1469-75

36) Roe CM, Mintun MA, Ghoshal N, et al. Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept. Neurology. 2010; 75: 42-8

37) Kemppainen NM, Aalto S, Karrasch M, et al. Cognitive reserve hypothesis: Pittsburgh Com-pound B and fluorodeoxyglucose positron emis-sion tomography in relation to education in mild Alzheimerʼs disease. Ann Neurol. 2008; 63: 112-8

38) Roe CM, Mintun MA, DʼAngelo G, et al. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol. 2008; 65: 1467-71

39) Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010; 67: 353-64

40) Landt J, DʼAbrera JC, Holland AJ, et al. Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar {beta}-amyloid in adults with down syndrome: safety, acceptability, and feasibility. Arch Neurol. 2011; 68: 890-6

41) Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007; 62: 229-34

42) Engler H, Santillo AF, Wang SX, et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2008; 35: 100-6

43) Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008; 64: 388-401

44) Villemagne VL, McLean CA, Reardon K, et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2009; 80: 998-1001

45) Hyare H, Ramlackhansingh A, Gelosa G, et al. 11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2011 Apr 8

46) Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinsonʼs disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008; 79: 1331-8

47) Burack MA, Hartlein J, Flores HP, et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology. 2010; 74: 77-84

48) Kantarci K, Yang C, Schneider JA, et al. Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging. 2010 Oct 18

49) Villemagne VL, Pike K, Pejoska S, et al. 11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report. J Alzheimers Dis. 2010; 19: 423-8

50) Fodero-Tavoletti MT, Rowe CC, McLean CA, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009; 50: 198-204

51) Stankoff B, Freeman L, Aigrot MS, et al. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-(1)(1)C]-2-(4ʼ-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol. 2011; 69: 673-80

52) Kadir A, Nordberg A. Target-specific PET probes for neurodegenerative disorders related to dementia. J Nucl Med. 2010; 51: 1418-30

53) Kudo Y, Okamura N, Furumoto S, et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimerʼs disease patients. J Nucl Med. 2007; 48: 553-61

54) Furukawa K, Okamura N, Tashiro M, et al. Amyloid PET in mild cognitive impairment and Alzheimerʼs disease with BF-227: comparison to FDG-PET. J Neurol. 2010; 257: 721-7

55) Waragai M, Okamura N, Furukawa K, et al. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimerʼs disease. J Neurol Sci. 2009; 285: 100-8

56) Shao H, Okamura N, Sugi K, et al. Voxel-based analysis of amyloid positron emission tomo-graphy probe [C]BF-227 uptake in mild cognitive impairment and alzheimerʼs disease. Dementia Geriatr Cogn Disord. 2010; 30: 101-11

57) Fodero-Tavoletti MT, Mulligan RS, Okamura N, et al. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol. 2009; 617(1-3): 54-8

58) Kikuchi A, Takeda A, Okamura N, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain. 2010; 133(Pt 6): 1772-8

59) Okamura N, Shiga Y, Furumoto S, et al. In vivo detection of prion amyloid plaques using [(11)C]BF-227 PET. Eur J Nucl Med Mol Imaging. 2010; 37: 934-41

60) Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006; 355: 2652-63

61) Small GW, Siddarth P, Burggren AC, et al. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without demen-tia. Arch Gen Psychiatry. 2009; 66: 81-7

62) Shin J, Lee SY, Kim SJ, et al. Voxel-based analysis of Alzheimerʼs disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage. 2010; 52: 488-96

63) Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimerʼs disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011; 10: 424-35

64) Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathol-ogy. JAMA. 2011; 305: 275-83

65) Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010; 68: 319-29

66) Jureus A, Swahn BM, Sandell J, et al. Charac-terization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem. 2010; 114: 784-94

67) Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimerʼs disease. Lancet Neurol. 2011; 10: 667-70

68) Villemagne VL, Ong K, Mulligan RS, et al. Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias. J Nucl Med. 2011; 52: 1210-7

69) Okamura N, Yanai K. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimerʼs disease. IDrugs. 2010; 13: 890-9

70) Bobinski M, Wegiel J, Wisniewski HM, et al. Neurofibrillary pathology--correlation with hippocampal formation atrophy in Alzheimer disease. Neurobiol Aging. 1996; 17: 909-19

71) Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003; 60: 729-36

72) Okamura N, Suemoto T, Furumoto S, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimerʼs disease. J Neurosci. 2005; 25: 10857-62

73) Fodero-Tavoletti MT, Okamura N, Furumoto S, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimerʼs disease. Brain. 2011; 134(Pt 4): 1089-100

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp